BIS Research Study Projects the Global Microbiome Therapeutics Market to Reach $3.20 Billion by 2032

News provided by

Jul 13, 2022, 08:00 ET

FREMONT, Calif., July 13, 2022 /PRNewswire/ -- The premium market intelligence study by BIS Research titled 'Microbiome Therapeutics Market – A Global and Regional Analysis' projects the market to reach $3.20 billion in terms of revenue by 2032, at a CAGR of 24.95%.

The study highlights the various emerging opportunities, such as several possibilities for current good manufacturing practice (cGMP) certified manufacturing facilities for live biotherapeutic products (LBPs), the entry of major players in the microbiome therapeutics domain, and the growing eminence of microbiome therapeutics for indications such as oncology and metabolic disease, which can be leveraged by players operating in the market.

The market intelligence by BIS Research additionally throws a spotlight on the key industry trends that have a humungous influence in shaping the industry in the future. The emergence of next-generation probiotics (NGPs) and microbial extracellular vesicles, the positive outcomes reported from the studies, and several other key trends are poised to change the market.

BIS Research study indicates that the rising geriatric population and positive consumer perception about microbiome therapeutics' potential benefits, coupled with the increasing adoption of inorganic growth strategies by key players in the market, among others, are driving the market growth.

The detailed study is a compilation of 33 market data tables and 120 figures spread through 195 pages and an in-depth TOC on "Global Microbiome Therapeutics Market – Analysis and Forecast, 2022-2032"

Demand – Drivers and Limitations

Following are the demand drivers for the global microbiome therapeutics market:

Growing strategic activities in microbiome therapeutics segment
Potential of microbiome therapeutics to address unmet needs of existing treatment options
Microbiome therapeutic products as a safer alternative to conventional drug treatments

The market is expected to face some limitations as well due to the following challenges:

Lack of uniformed standardized regulatory guidelines
Associated safety issues with live biotherapeutic products (LBPs)
Storage issues with live micro-organisms
Challenges associated with manufacturing of LBPs

Reasons to Buy this Report

This exclusive report on the global microbiome therapeutics market will help in the following ways:

Aid in product development
Help in targeting a segment for launching a new product
Offer go-to-market strategies for different source types
Assist in exploring the newer application
Pipeline analysis and competitive landscaping of key players
Support in analyzing the competitors' funding and patent scenario
Partnership landscaping

Analyst's Take on the Market:

According to Tausif Qudsi, Principal Analyst – BIS Research, "Global microbiome therapeutics market is expected to grow further in the coming years due to the continuous increase in awareness and need for better and safer treatment alternatives and the dominance of gastrointestinal (GI) and infectious diseases segment can be attributed to the existing dominance of microbiome therapeutics available for a variety of indications ranging from diarrhea and gut dysbiosis to skin disorders and cancer indications, among others. The gastrointestinal and infectious diseases segment market is expected to increase due to the possible introduction of late-stage candidates exclusively developed for GI indications. It is anticipated that the positive findings from the ongoing clinical trials will serve as another shot for the segment to witness significant growth in the coming years."

View the report on the Global Microbiome Therapeutics Market

Key Companies Operating in the Market and Competitive Landscape

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

Some prominent names established in this market are mentioned as follows:

4D pharma plc
Seres Therapeutics, Inc.
Microbiotica
Enterome
Enterome Biosciences
Destiny Pharma plc
Taisho Pharmaceutical Holdings
AOBiome Therapeutics, Inc.
Finch Therapeutics Group, Inc.
Rebiotix Inc. (a Subsidiary of Ferring Pharmaceuticals)
MaaT Pharma
Vedanta Biosciences Inc.
OxThera AB
Pendulum Therapeutics
Caelus Health
Quorum Innovations
Sanofi S.A.
DermBiont, Inc.
EnteroBiotix Ltd
YSOPIA Bioscience
Winclove Probiotics
TargEDys
Evelo Biosciences, Inc.
BiomX
Biomica Ltd.
Scioto Biosciences, Inc.
Lactobio A/S

Who should buy this report?

Emerging players who are developing microbiome therapeutics
Existing companies offering microbiome therapeutics

Request a Sample of this Report

Key Questions Answered in the Report:

What are microbiome therapeutics products?
How has microbiome therapeutics evolved over the years since its inception?
What are the major market drivers, challenges, and opportunities in the global microbiome therapeutics market?
What are the potential indications targeted using microbiome therapeutics products?
What does the pipeline for the microbiome therapeutics products market look like?
What is the market size and future potential of microbiome therapeutics products?
What are the major market drivers, challenges, and opportunities in the global microbiome therapeutics products market?
How does the clinical trial landscape look for the global microbiome therapeutics products market?
What was the impact of COVID-19 on this market?
Which region is expected to contribute the highest revenue to the global microbiome therapeutics products market during the forecast period?
What are the key development strategies implemented by the major players in order to sustain them in the competitive market?
What are the key strategies that have been used by leading players in the global microbiome therapeutics market for the development of microbiome therapeutics?

BIS Research Related Market Studies:

Global Human Microbiome Modulators Market
Global Skin Microbiome Modulators Market
Global Cancer Microbiome Sequencing Market

About BIS Research:

BIS Research is a global B2B market intelligence and advisory firm focusing on deep technology and related emerging trends that can disrupt the market dynamics in the near future. We publish more than 200 market intelligence studies annually that focus on several deep technology verticals.

Our strategic market analysis emphasizes market estimations, technology analysis, emerging high-growth applications, deeply segmented granular country-level market data, and other important market parameters useful in the strategic decision-making for senior management.

BIS Research offers syndicate as well as custom studies and expert consultations to firms, providing them specific and actionable insights on novel technology markets, business models, and competitive landscape.

BIS Healthcare vertical offers intelligence in the healthcare technology market for medical devices, digital health, life sciences, robotics and imaging, information technology, precision medicine, and other emerging healthcare technologies, covering the entire industry spectrum.

Contact:
Head of Marketing
Email: [email protected]
+1-510-404-8135
BIS Research Inc.
39111 PASEO PADRE PKWY STE 313,
FREMONT CA 94538-1686
Visit our Blog @ https://bisresearch.com/news
Connect with us on LinkedIn @ https://www.linkedin.com/company/bis-research
Connect with us on Twitter@ https://twitter.com/BISResearch